Epstein-Barr virus reactivation in a patient treated with anti-thymocyte globulin for severe aplastic anemia

American Journal of Hematology

Volumn 81, Issue 5, 2006, Pages 355-357

  Calistri, Elisabetta ^a   Tiribelli, Mario ^a   Battista, Marta ^a   Michelutti, Angela ^a   Corbellino, Mario ^b   Viale, Pierluigi ^a   Fanin, Renato ^a   Damiani, Daniela ^a  

^a UNIVERSITY HOSPITAL OF UDINE   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Anti thymocyte globulin; Epstein Barr virus; Rituximab; Severe aplastic anemia

Indexed keywords

CYCLOSPORIN; MEROPENEM; METHYLPREDNISOLONE; RITUXIMAB; THYMOCYTE ANTIBODY;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS; HUMAN; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INFECTIOUS MONONUCLEOSIS; MALE; PRIORITY JOURNAL; VIRUS INFECTION; VIRUS REACTIVATION;

ADULT; ANEMIA, APLASTIC; ANTILYMPHOCYTE SERUM; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; OPPORTUNISTIC INFECTIONS;

EID: 33646475755     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20560     Document Type: Article

References (11)

1. van Esser JWJ, van der Holt B, Meijer E, et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood 2001;98:972-988.
2. Young NS. Acquired aplastic anemia. Ann Intern Med 2002;136:534-546.
3. Champlin R, Ho W, Gale RP. Antithymocyte globulin treatment in patients with aplastic anemia: a prospective randomized trial. New Engl J Med 1983;308:113-118.
4. Doney K, Martin P, Storb R, et al. A randomized trial of antihuman thymocyte globulin versus murine monoclonal antihuman T-cell antibodies as immunosuppressive therapy for aplastic anemia. Exp Hematol 1985;13:520-524.
5. Bacigalupo A. Antilymphocyte/thymocyte globulin for graft versus host disease prophylaxis: efficacy and side effects. Bone Marrow Transpl 2005;35:225-231.
6. Haque T, Thomas JA, Parratt R, et al. A prospective study in heart and lung transplant recipients correlating persistent Epstein-Barr virus infection with clinical events. Transplantation 1997;64:1028-1034.
7. Hudnall SD, Patel J, Schwab H, Martinez J. (2003) Comparative immunophenotypic features of EBV-positive and EBV-negative atypical lymphocytosis. Cytometry B Clin Cytom 2003;55:22-28.
8. Aalto SM, Juvonen E, Tarkkanen J, et al. Lymphoproliferative disease after allogeneic stem cell transplantation-pre-emptive diagnosis by quantification of Epstein-Barr virus DNA in serum. J Clin Virol 2003;28:275-283.
9. Wagner HJ, Cheng YC, Huls MH, et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood 2004;103:3979-3981.
10. Faye A, Quartier P, Reguerre Y, et al. Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children. Br J Haematol 2001;115:112-118.
11. Milpied N, Vasseur B, Parquet N, et al. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol 2000;11(S1):113-116.